Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

April 12, 2022

Bioasis teams up with pharma giant Janssen on drug-delivery platform

Photo | Contributed Deborah Rathjen, executive chair at New Haven's Bioasis Technologies.

New Haven’s Bioasis Technologies will team up with Janssen Biotech on research into its xB3TM technology for delivering drugs across the blood-brain barrier, the company announced Monday.

The deal gives Janssen the option to research, develop and commercialize products based on Bioasis’ xB3TM platform, 

Terms of the deal, which was facilitated by Johnson & Johnson Innovation,  were not disclosed. Janssen is a wholly-owned subsidiary of Johnson & Johnson based in Belgium.

Bioasis Executive Chair Deborah Rathjen said, “We are very pleased to have entered into this agreement and excited to be working with Janssen. Our xB3TM BBB drug delivery platform has the potential to significantly advance the treatment of disease, solving a major unmet clinical need and improving the lives of patients.” 

Bioasis’ xB3 platform uses a human transport protein found circulating at low levels in the blood to shuttle molecules across the blood-brain barrier. Among the potential treatments that can be transported into the brain using xB3 are monoclonal antibodies, enzymes, small molecules, small-interfering RNA and other types of gene therapies, according to preclinical studies.

Bioasis’ drug-development efforts focus on brain cancers, Gaucher’s disease and neurodegenerative disorders including Parkinson’s disease and Lewy Body Dementia.

Last year Bioasis announced a research partnership with a UK biotech, closed on $2.4 million in debt financing and named a former PwC audit partner as its new chief financial officer.

Contact Liese Klein at

Sign up for Enews


Order a PDF